natgillin/translations-raw huggingface dataset:
There is no safety or efficacy information on the use of Ribavirin with other forms of interferon (i.e.,
Ni podatkov o varnosti ali učinkovitosti uporabe ribavirina z ostalimi oblikami interferonov (tj. ne
• are pregnant or planning to become pregnant (see section “Pregnancy and breast-feeding”).
• če ste noseči ali načrtujete nosečnost (glejte poglavje „Nosečnost in dojenje“),
Both ribavirin and its triazole carboxamide and triazole carboxylic acid metabolites are also excreted
Tako ribavirin kot njegovi triazolski karboksamidni in triazolski karboksikislinski presnovki se izločajo tudi prek ledvic.
- If you have or develop severe kidney or liver problems, this treatment will be stopped.
- Če imate hude težave z ledvicami ali jetri oz. če se tovrstne težave pojavijo, bo zdravljenje
Results of in vitro studies using both human and rat liver microsome preparations indicated no cytochrome P450 enzyme mediated metabolism of ribavirin.
Izsledki študij in vitro z uporabo pripravkov človeških in podganjih jetrnih mikrosomov niso pokazali nikakršne presnove ribavirina prek encimov citokroma P450.
Important treatment-emergent adverse reactions that occurred in this patient population were nervousness (8 %), aggression (3 %), anger (2 %), depression/depressed mood (4 %) and hypothyroidism (3 %) and 5 subjects received levothyroxine treatment for hypothyroidism/elevated TSH.
Pomembni neželeni učinki, ki so se pojavili med zdravljenjem pri tej populaciji bolnikov, so bili živčnost (8 %), agresivnost (3 %), jeza (2 %), depresija in depresivno razpoloženje (4 %) ter hipotireoza (3 %), 5 preizkušancev pa je prejelo zdravljenje z levotiroksinom zaradi hipotireoze oziroma zvišane vrednosti TSH.
• are a woman of childbearing age (see section “Pregnancy and breast-feeding”).
• ženska v rodni dobi (glejte poglavje „Nosečnost in dojenje“).
Acute hypersensitivity: If an acute hypersensitivity reaction (e.g., urticaria, angioedema, bronchoconstriction, anaphylaxis) develops, Ribavirin must be discontinued immediately and appropriate medical therapy instituted.
Akutna preobčutljivost: Če se razvije akutna preobčutljivostna reakcija (npr. urtikarija, angioedem, bronhokonstrikcija, anafilaksa), morate jemanje ribavirina takoj prekiniti in uvesti ustrezno zdravljenje.
Thus, patients who develop fatigue, somnolence, or confusion during treatment must be cautioned to avoid driving or
Bolnike, ki so med zdravljenjem utrujeni, zaspani ali zmedeni, morate torej opozoriti, da ne smejo
The response to treatment in both of these trials is presented in Table 7.
V Preglednici 7 je predstavljen odziv bolnikov na zdravljenje pri obeh preskušanjih.
Ribavirin clinical trials in children and adolescents:
Klinična preskušanja pri otrocih in mladostnikih:
You may want to consider asking a family member or close friend to help you stay alert to signs of depression or changes in your behaviour.
Po potrebi prosite družinskega člana ali dobrega prijatelja, naj vam pomaga biti pozoren na znake
One film-coated tablet contains 200 mg ribavirin.
Ena filmsko obložena tableta vsebuje 200 mg ribavirina.
- Hypersensitivity to the active substance or to any of the excipients.
− Preobčutljivost za zdravilno učinkovino ali katerokoli pomožno snov;
If needed, 2nd dose reduction of Ribavirin BioPartners is by an additional 200 mg/day.
Če je potrebno, lahko opravite tudi drugo zmanjšanje odmerka zdravila Ribavirin BioPartners za dodatnih 200 mg/dan.
Because of the potential for adverse reactions in breast-fed infants, breast-feeding must be discontinued prior to initiation of
Zaradi nevarnosti za pojav neželenih učinkov pri dojenih dojenčkih je treba pred zdravljenjem prenehati z dojenjem.
The major treatment-related change was a reversible mild to moderate anaemia, the severity of which was greater than that produced by either active substance alone.
Glavna sprememba v zvezi z zdravljenjem je bila reverzibilna, blaga do zmerna anemija, ki je bila hujša kot pri samostojni uporabi vsake od obeh učinkovin.
• Genotype Non-1: The decision to extend therapy to one year in patients with negative HCVRNA after six months of treatment should be based on other prognostic factors (e.g., age > 40 years, male gender, bridging fibrosis).
• Genotip ne-1: Odločitev o podaljšanju terapije na eno leto pri bolnikih z negativno vrednostjo serumske RNA-HCV po šestih mesecih zdravljenja mora temeljiti na drugih prognostičnih dejavnikih (npr. starost > 40 let, moški spol, premostitvena fibroza).
- severe rashes which may be associated with blisters in the mouth, nose, eyes and other mucosal membranes (erythema multiforme, Stevens Johnson syndrome), toxic epidermal necrolysis (blistering and peeling of the top layer of skin).
hude osipe, ki so lahko povezani z mehurji v ustih, nosu, očeh ali na drugih sluznicah (eritema multiforme, Stevens-Johnsonov sindrom), toksična epidermalna nekroliza (nastajanje mehurjev in luščenje vrhnje plasti kože).
As in adult patients, children and adolescents also experienced other psychiatric adverse reactions (e.g., depression, emotional lability, and somnolence) (see section 4.4).
Kot odrasli bolniki so imeli tudi otroci in mladostniki še druge psihiatrične neželene reakcije (npr. depresijo, čustveno labilnost in zaspanost) (glejte poglavje 4.4).
When deciding to not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition.
Ko se odločate, ali boste pri posameznem bolniku uvedli ali odložili zdravljenje do odrasle dobe, je pomembno upoštevati, da kombinirana terapija povzroči zastoj rasti.
The adverse reactions listed in Table 4 are based on experience from clinical trials in adult naïve patients treated for 1 year and post-marketing use.
Neželeni učinki, ki so navedeni v Preglednici 4, so povzeti iz izkušenj, zbranih v kliničnih preskušanjih pri odraslih bolnikih, ki se še niso zdravili s tem zdravilom in so jih z njim zdravili eno leto, ter iz obdobja trženja zdravila.
This decline was significant among responders (-0.3 for Metavir and -1.2 for Ishak) and stable (-0.1 for Metavir and -0.2 for Ishak) among non-responders.
Ta upad je bil statistično značilen pri bolnikih, ki so se odzvali na zdravljenje (-0,3 pri oceni po Metavirju in -1,2 pri oceni po Ishaku) in stabilen (-0,1 pri oceni po Metavirju in -0,2 pri oceni po Ishaku) pri tistih, ki se niso odzvali na zdravljenje.
Food effect: The bioavailability of a single oral dose of ribavirin was increased by co-administration of a high fat meal (AUCtf and Cmax both increased by 70 %).
Učinek hrane: Biološka uporabnost enkratnega peroralnega odmerka ribavirina se je povečala ob sočasnem zaužitju zdravila z zelo mastnim obrokom (tako AUCtf kot Cmax sta se povečala za 70 %).
During treatment with Ribavirin BioPartners in combination therapy with an alpha interferon, patients may experience eye problems, or loss of vision in rare instances.
Med zdravljenjem s kombinacijo zdravila Ribavirin BioPartners z interferonom alfa imajo lahko bolniki težave z očmi ali v redkih primerih izgubijo vid.
Stevens Johnson syndrome*, toxic epidermal necrolysis*, Musculoskeletal and connective tissue disorders Very common:
Stevens-Johnsonov sindrom*, toksična epidermalna nekroliza*, multiformni eritem* Bolezni mišično-skeletnega sistema in vezivnega tkiva Zelo pogosti:
As in adult patients, children and adolescents experienced other psychiatric adverse reactions (e.g. depression, emotional lability, and somnolence).
Tako kot pri odraslih bolnikih so tudi pri otrocih in mladostnikih opazili druge psihiatrične neželene reakcije (npr. depresijo, čustveno labilnost in zaspanost).
Potential to exacerbate immunosuppression: Pancytopenia and bone marrow suppression have been reported in the literature to occur within 3 to 7 weeks after the administration of a peginterferon and ribavirin concomitantly with azathioprine.
Možnost za poslabšanje imunosupresije: V literaturi so poročali o pancitopeniji in supresiji kostnega mozga, ki sta se pojavili v 3 do 7 tednih po dajanju peginterferona in ribavirina sočasno z azatioprinom.
Serum Creatinine
Kreatinin v serumu
Any potential for interactions may persist for up to two months (five half-lives for ribavirin) after cessation of ribavirin therapy due to the long half-life (see section 5.2).
Zaradi dolge razpolovne dobe lahko do medsebojnega delovanja pride še do dva meseca (5 razpolovnih dob ribavirina) po koncu terapije z ribavirinom (glejte poglavje 5.2).
Ribavirin therapy must not be initiated until a report of a negative pregnancy test has been obtained immediately prior to initiation of therapy.
Zdravljenja z ribavirinom ne smete uvesti, dokler ne dobite negativnega izvida nosečnostnega testa tik pred začetkom zdravljenja.
Ribavirin (800-1,200 mg /day)
Ribavirin (800-1.200 m g/dan ) d +
As adherence might be of importance for outcome of therapy, the dose should be kept as close as possible to the recommended standard dose.
Ker je upoštevanje terapije lahko pomembno za izid zdravljenja, naj bo odmerek čim bližje priporočenemu standardnemu odmerku, saj ni mogoče izključiti morebitnega negativnega vpliva zmanjšanja odmerka ribavirina na učinkovitost
Within the organ system classes, adverse reactions are listed under headings of frequency using the following categories: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥ 1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000); not known.
Neželeni učinki so navedeni po organskih sistemih, z naslednjimi kategorijami pogostnosti: zelo pogosti (≥1/10), pogosti (od ≥1/100 do <1/10), občasni (od ≥1/1.000 do <1/100), redki (od ≥ 1/10.000 do <1/1.000), zelo redki (<1/10.000), neznana.
In clinical trials of 118 children and adolescents 3 to 16 years of age treated with combination therapy of interferon alfa-2b and ribavirin, 6 % discontinued therapy due to adverse reactions.
V kliničnih preskušanjih pri 118 otrocih in mladostnikih, starih od 3 do 16 let zdravljenih s kombinacijo interferona alfa-2b in ribavarina, so pri 6 % ukinili terapijo zaradi neželenih reakcij.
For children or adolescents who cannot swallow a film-coated tablet, an oral solution of ribavirin is available.
Za otroke in mladostnike, ki ne morejo požirati filmsko obloženih tablet, je na voljo peroralna raztopina ribavirina.
- various laboratory blood values abnormalities.
različne neobičajne vrednosti laboratorijskih preiskav.
If your female partner is not pregnant now but is of childbearing age, she must be tested for pregnancy each month during treatment and for the 7 months after treatment has stopped.
Če je vaša partnerka v rodni dobi, toda trenutno ni noseča, mora med zdravljenjem opraviti test nosečnosti vsak mesec ter še 7 mesecev po
Men whose partners are pregnant must be instructed to use a condom to minimise delivery of ribavirin
Moškim z nosečo partnerko naročite, naj uporabljajo kondom, da se čimbolj zmanjša
The regimen administered should be selected based on the anticipated efficacy and safety of the combination treatment for an individual patient (see section 5.1).
Izbira režima kombiniranega zdravljenja je odvisna od značilnosti bolnika, izbira terapevtske sheme pa mora temeljiti na pričakovani učinkovitosti in varnosti kombinirane terapije za vsakega posameznega bolnika (glejte poglavje 5.1).
* Since ribavirin is always prescribed with an alpha interferon product, and the listed adverse drug reactions included reflecting post-marketing experience do not allow precise quantification of frequency, the frequency reported above is from clinical trials using ribavirin in combination with interferon alfa-2b (pegylated or non-pegylated).
* Ker ribavirin vedno predpisujejo skupaj z zdravili, ki vsebujejo interferon alfa, in ker našteti neželeni učinki temeljijo na izkušnjah v obdobju trženja in ne omogočajo natančne opredelitve pogostnosti, so zgoraj navedene pogostnosti vzete iz kliničnih preskušanj z uporabo ribavirina v kombinaciji z interferonom alfa-2b (pegiliranim ali nepegiliranim).
Reports of mitochondrial toxicity, in particular lactic acidosis and pancreatitis, of which some fatal, have been reported (see section 4.4).
Objavljena so bila poročila o primerih mitohondrijske toksičnosti, še posebej v obliki laktacidoze in pankreatitisa, in nekateri od njih so vodili do bolnikove smrti (glejte poglavje 4.4).
In a juvenile rat toxicity study, pups dosed from postnatal day 7 to 63 with 10, 25 and 50 mg/kg of ribavirin demonstrated a dose-related decrease in overall growth, which was subsequently manifested as slight decreases in body weight, crown-rump length and bone length.
V študiji toksičnosti zdravila za podganje mladiče so pri mladičih, ki so jim od 7. do 63. dne po rojstvu dajali odmerke 10, 25 in 50 mg/kg ribavirina, so ugotovili od odmerka odvisno splošno zmanjšanje rasti, ki se je kasneje pokazalo kot rahlo zmanjšanje telesne mase, razdalje od temena do trtice in dolžine kosti.
Ribavirin BioPartners does not affect your ability to drive or use machines; however, interferon alfa-2b may affect your ability to drive or use machines.
Zdravilo Ribavirin BioPartners ne vpliva na vašo sposobnost za vožnjo ali upravljanje s stroji, vendar pa interferon alfa-2b vpliva na vašo sposobnost za vožnjo ali upravljanje s stroji.
The mechanism by which ribavirin in combination with interferon alfa-2b exerts its effects against HCV is unknown.
Mehanizem delovanja, prek katerega ribavirin v kombinaciji z interferonom alfa-2b deluje proti HCV, ni znan.
In general, the adverse reaction profile in the limited children and adolescent population studied was similar to that observed in adults, although there is a paediatric-specific concern regarding growth inhibition, as decrease in height percentile (mean percentile decrease of 9 percentile) and weight percentile (mean percentile decrease of 13 percentile) were observed during treatment.
Na splošno je bil profil neželenih reakcij v omejeni proučevani populaciji otrok in mladostnikov podoben profilu pri odraslih, čeprav se je pri njih pojavila dodatna skrb glede zaviranja rasti, saj so med zdravljenjem opažali zmanjšanje percentila telesne višine (srednje percentilno zmanjšanje za 9 percentilov) in percentila telesne mase (srednje odstotno zmanjšanje za 13 percentilov).
If you are pregnant, you must not take Ribavirin BioPartners.
Če ste noseči, ne smete jemati zdravila Ribavirin BioPartners.
The Kaplan-Meier estimate for continued sustained response over 5 years is 97 % (95 % CI: 95-99 %) for patients receiving non-pegylated interferon alfa-2b (with or without ribavirin), and is 99 % (95 % CI: 98-100 %) for patients receiving pegylated interferon alfa-2b (with or without ribavirin).
Kaplan-Meierjeva ocena nadaljnjega neprekinjenega trajnega odziva v času 5 let je znašala 97 % (95 % IZ: 95-99 %) pri bolnikih, ki so prejemali nepegiliran interferon alfa-2b (z ali brez ribavirina), oziroma 99 % (95 % IZ: 98-100 %) pri tistih, ki so prejemali pegiliran interferon alfa-2b (z ali brez
If pregnancy does occur during treatment or within four months from stopping treatment, the patient must be advised of the significant teratogenic risk of ribavirin to the foetus.
Če bolnica med zdravljenjem ali v roku štirih mesecev po koncu zdravljenja kljub temu zanosi, jo morate opozoriti na veliko teratogenost ribavirina za plod.
In this study, the most prevalent adverse reactions in all subjects were pyrexia (80 %), headache (62 %), neutropenia (33 %), fatigue (30 %), anorexia (29 %) and injection-site erythema (29 %).
V tej študiji so bili neželeni učinki z največjo prevalenco pri vseh preizkušancih zvišana telesna temperatura (80 %), glavobol (62 %), nevtropenija (33 %), utrujenost (30 %), anoreksija (29 %) in eritem na mestu injiciranja (29 %).
In those patients that received > 10.6 mg/kg ribavirin (800 mg dose in typical 75 kg patient), regardless of genotype or viral load, response rates were significantly higher than in those patients that received ≤ 10.6 mg/kg ribavirin (Table 6), while response rates in patients that received > 13.2 mg/kg ribavirin were even
Pri bolnikih, ki so prejeli > 10,6 mg/kg ribavirina (800 mg odmerek pri tipičnem bolniku s telesno maso 75 kg, je bil delež odziva bistveno višji kot pri tistih, ki so prejeli ≤ 10,6 mg/kg ribavirina (Preglednica 6), ne glede na genotip ali virusno obremenitev, delež odziva pri tistih, ki so prejeli > 13,2 mg/kg zdravila
Female patients: Ribavirin must not be used by females who are pregnant (see sections 4.3 and 5.3).
Bolnice: Nosečnice ne smejo uporabljati ribavirina (glejte poglavja 4.3 in 5.3).
Approximately 12 to 21 % of children treated with ribavirin and interferon alfa-2b (pegylated and nonpegylated) developed increase in thyroid stimulating hormone (TSH).
Pri približno 12 do 21 % otrok, zdravljenih z ribavirinom in interferonom alfa-2b (pegiliranim in nepegiliranim), se je pojavilo povečanje vrednosti tiroidee stimulirajočega hormona (TSH).
The longer term data available in children treated with the combination therapy with standard interferon/ribavirin are also indicative of substantial growth retardation (> 15 percentile decrease in height percentile as compared to baseline) in 21 % of children despite being off treatment for more
Dolgoročnejši podatki, ki so na voljo pri otrocih, zdravljenih s kombinirano terapijo s standardnim interferonom in ribavirinom, so tudi pokazali znatno zaostajanje v rasti (zmanjšanje telesne višine za > 15 percentilov v primerjavi z osnovno vrednostjo) pri 21 % otrok, kljub temu, da se ti že več kot 5 let niso zdravili s tem zdravilom.
Three trials examined the use of interferon in naïve patients, two with ribavirin + interferon alfa-2b (C95-132 and I95-143) and one with ribavirin + peginterferon alfa-2b (C/I98-580).
V treh preskušanjih so raziskovali uporabo interferona pri predhodno nezdravljenih bolnikih in sicer v dveh z ribavirinom + interferonom alfa-2b (C95-132 in I95-143) in v eni z ribavirinom + peginterferonom alfa-2b (C/I98-580).
Ocular changes: Ribavirin is used in combination therapy with alpha interferons.
Očesne spremembe: Ribavirin uporabljamo za kombinirano terapijo z interferoni alfa.
2 tablets in the morning and 2 tablets in the evening see adult dose and corresponding number of film-coated tablets
2 tableti zjutraj in 2 tableti zvečer glejte odmerjanje za odrasle in ustrezno število filmsko obloženih tablet Predpisani odmerek zaužijte z vodo, med jedjo.
Among children and adolescents, treated with ribavirin in combination with interferon alfa-2b, suicidal ideation or attempts were reported more frequently compared to adult patients (2.4 % versus 1 %) during treatment and during the 6-month follow-up after treatment.
Pri otrocih in mladostnikih zdravljenih z ribavirinom v kombinaciji z interferonom alfa-2b, so pogosteje poročali o samomorilnih mislih ali poskusu samomora kot pri odraslih (2,4 % v primerjavi z 1 %) med zdravljenjem in v času 6-mesečnega spremljanja bolnikov po zdravljenju.
Mitochondrial toxicity and lactic acidosis:
Toksičnost za mitohondrije in laktacidoza:
During the course of interferon (standard and pegylated)/ribavirin therapy lasting up to 48 weeks in patients ages 3 through 17 years, weight loss and growth inhibition were common (see sections 4.8 and 5.1).
Med kombinirano terapijo z interferonom (standardnim in pegiliranim) ter ribavirinom, ki traja do 48 tednov, sta bila pri bolnikih, starih od 3 do 17 let, hujšanje in zavora rasti pogosta (glejte poglavji 4.8 in 5.1).
Anaemia (haemoglobin < 9.4 g/dl) was reported in 12 % (23/194) of patients treated with ribavirin in combination with peginterferon alfa-2b.
O anemiji (hemoglobin < 9,4 g/dl) so poročali pri 12 % (23/194) bolnikov, zdravljenih z ribavirinom v kombinaciji s peginterferonom alfa-2b.
There is no evidence that ribavirin interacts with non-nucleoside reverse transcriptase inhibitors or
Ni dokazov o medsebojnem delovanju ribavirina z nenukleozidnimi zaviralci reverzne transkriptaze
Following oral dosing with 600 mg BID, steady-state was reached by approximately four weeks, with mean steady state plasma concentrations approximately 2,200 ng/ml.
Po peroralnem odmerjanju ribavirina 600 mg dvakrat na dan je bilo stanje dinamičnega ravnovesja doseženo v približno štirih tednih; srednja plazemska koncentracija v stanju dinamičnega ravnovesja je bila približno 2.200 ng/ml.
Within the organ system classes, adverse reactions are listed under headings of frequency using the following categories: very common (≥ 1/10); common (≥ 1/100 to < 1/10), and uncommon (≥ 1/1,000 to < 1/100).
Neželeni učinki so navedeni po organskih sistemih, z naslednjimi kategorijami pogostnosti: zelo pogosti (≥1/10); pogosti (od ≥1/100 do <1/10) in občasni (od ≥1/1.000 do <1/100).
Subjects with impaired renal function should be more carefully monitored with respect to the development of anaemia.
Pri preiskovancih z okvarjeno ledvično funkcijo je potrebno bolj skrbno spremljanje, da ugotovite morebiten nastanek anemije.
4 tablets b Refer to adult dosing table (Table 1)
4 tableteb Glejte preglednico odmerjanja pri odraslih bolnikih (preglednica 1)
Interferon alfa-2b (pegylated and non-pegylated) therapy may be initiated if TSH levels can be maintained in the normal range by medication.
Terapijo z interferonom alfa-2b (pegiliranim in nepegiliranim) lahko uvedete, če boste lahko z zdravili ohranjali vrednost TSH v normalnem razponu.
Patients who are treated with interferon alfa-2b and ribavirin after previous relapse from interferon therapy or who are treated for a shorter period are likely to have an improved safety profile than that
Pri bolnikih, ki se zdravijo z interferonom alfa-2b in ribavirinom po predhodni ponovitvi bolezni po terapiji z interferonom, ali pri tistih, ki se zdravijo krajši čas, bo varnostni profil verjetno boljši od
Transfer into seminal fluid: Seminal transfer of ribavirin has been studied.
Prehajanje v semensko tekočino: Proučevali so prehajanje ribavirina v semensko tekočino.
Patients treated with ribavirin and zidovudine are at increased risk of developing anaemia; therefore, the concomitant use of ribavirin with zidovudine is not recommended (see section 4.5).
Bolniki, zdravljeni z ribavirinom in zidovudinom, imajo povečano tveganje za pojav anemije, zato pri njih sočasna uporaba ribavirina in zidovudina ni priporočljiva (glejte poglavje 4.5).
During the one year of treatment with ribavirin in combination with interferon alfa-2b, some children and adolescents did not grow or gain weight as much as expected.
V času enoletnega zdravljenja z zdravilom Ribavirin BioPartners v kombinaciji z interferonom alfa-2b nekateri otroci in mladostniki niso zrasli in niso pridobili na telesni masi toliko, kot bi pričakovali.
• are allergic (hypersensitive) to ribavirin or any of the other ingredients of Ribavirin BioPartners
• če ste alergični (preobčutljivi) na ribavirin ali katerokoli sestavino zdravila Ribavirin
Ribavirin monotherapy must not be used.
Zdravila Ribavirin ne smete uporabljati v monoterapiji.
Other CNS effects including aggressive behaviour (sometimes directed against others such as homicidal ideation), bipolar disorder, mania, confusion and alterations of mental status have been observed with alpha interferons.
Opažali so tudi druge učinke interferonov alfa na CŽS, vključno z agresivnostjo (ki je včasih usmerjena proti drugim kot je ideja o umoru), bipolarna motnja, manija, zmedenostjo in spremembami duševnega statusa.
This benefit was maintained irrespective of standard predictors of response to interferon alfa-2b such as virus level, HCV genotype
Ta koristen učinek se je ohranjal ne glede na standardne napovedne dejavnike odziva na interferon alfa-2b, npr. virusno breme, HCV genotip in histološka stopnja bolezni.
Standard blood tests will be taken to check your blood, kidney and liver function.
Za kontrolo vaše krvi, ledvic in funkcije jeter vam bodo izvajali standardne krvne preiskave.
- This medicine has been prescribed for you.
− Zdravilo je bilo predpisano vam osebno in ga ne smete dajati drugim.
Please refer also to the interferon alfa-2b Summary of Product Characteristics (SPC) for prescribing information particular to that product.
Glejte tudi povzetek glavnih značilnosti zdravila za interferon alfa-2b za specifične informacije za predpisovanje tega zdravila (Summary of Product Characteristics- SPC).